One-year outcomes of resveratrol supplement with aflibercept versus aflibercept monotherapy in wet age-related macular degeneration.
Ioannis DatserisNikolaos BouratzisCharalambos KotronisIordanis DatserisMalvina-Efthimia TzanidakiAlexandros RouvasNikolaos GouliopoulosPublished in: International journal of ophthalmology (2023)
The resveratrol oral supplement is a complementary treatment in cases of wet AMD, highlighting its effectiveness in improving patients' QoL status.
Keyphrases
- age related macular degeneration
- end stage renal disease
- ejection fraction
- chronic kidney disease
- randomized controlled trial
- newly diagnosed
- systematic review
- combination therapy
- prognostic factors
- clinical trial
- adipose tissue
- skeletal muscle
- insulin resistance
- replacement therapy
- study protocol
- glycemic control
- double blind